Yat Sun Or's most recent trade in Enanta Pharmaceuticals Inc was a trade of 5,225 Common Stock done . Disclosure was reported to the exchange on Feb. 12, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 5,225 | 378,267 (1%) | 0% | 0 | Common Stock | |
| Enanta Pharma Inc | Dr. Yat Sun Or | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 5,225 | 378,267 (1%) | 0% | 0 | - | |
| Enanta Pharma Inc | Dr. Yat Sun Or | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 5,225 | 378,267 (1%) | 0% | 0 | - | |
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.25 per share. | 12 Feb 2026 | 3,413 | 374,854 (1%) | 0% | 14.2 | 48,635 | Common Stock |
| Enanta Pharma Inc | Dr. Yat Sun Or | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.25 per share. | 12 Feb 2026 | 3,413 | 374,854 (1%) | 0% | 14.2 | 48,635 | - |
| Enanta Pharma Inc | Dr. Yat Sun Or | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.25 per share. | 12 Feb 2026 | 3,413 | 374,854 (1%) | 0% | 14.2 | 48,635 | - |
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 1,650 | 373,042 (1%) | 0% | 0 | Common Stock | |
| Enanta Pharma Inc | Dr. Yat Sun Or | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 1,650 | 373,042 (1%) | 0% | 0 | - | |
| Enanta Pharma Inc | Dr. Yat Sun Or | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 1,650 | 373,042 (1%) | 0% | 0 | - | |
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 14.23 per share. | 05 Dec 2025 | 2,390 | 371,392 (1%) | 0% | 14.2 | 34,010 | Common Stock |
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.12 per share. | 01 Dec 2025 | 753 | 373,782 (1%) | 0% | 14.1 | 10,632 | Common Stock |
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Chief Scientific Officer | 25 Nov 2025 | 110,000 | 110,000 | - | - | Stock Option (right to buy) | ||
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 9,750 | 378,859 (1%) | 0% | 0 | Common Stock | |
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.59 per share. | 12 Feb 2025 | 4,324 | 374,535 (1%) | 0% | 5.6 | 24,171 | Common Stock |
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 8.06 per share. | 06 Dec 2024 | 2,591 | 369,109 (1%) | 0% | 8.1 | 20,883 | Common Stock |
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.60 per share. | 01 Dec 2024 | 1,595 | 371,700 (1%) | 0% | 8.6 | 13,717 | Common Stock |
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Chief Scientific Officer | 27 Nov 2024 | 87,000 | 87,000 | - | - | Stock Option (right to buy) | ||
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 3,680 | 374,375 (1%) | 0% | 0 | Common Stock | |
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.41 per share. | 12 Feb 2024 | 1,080 | 373,295 (1%) | 0% | 12.4 | 13,403 | Common Stock |
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Sr. VP, R&D & CSO | Sale of securities on an exchange or to another person at price $ 9.63 per share. | 05 Dec 2023 | 2,412 | 370,695 (1%) | 0% | 9.6 | 23,228 | Common Stock |
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Sr. VP, R&D & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.49 per share. | 01 Dec 2023 | 1,595 | 373,107 (1%) | 0% | 9.5 | 15,137 | Common Stock |
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Sr. VP, R&D & CSO | 22 Nov 2023 | 86,000 | 86,000 | - | - | Stock Option (right to buy) | ||
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Sr. VP & CSO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.00 per share. | 15 Mar 2023 | 13,925 | 388,627 (1%) | 0% | 14 | 194,950 | Common Stock |
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Sr. VP & CSO | 15 Mar 2023 | 13,925 | 0 | - | - | Stock Option (Right to Buy) | ||
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Sr. VP & CSO | Sale of securities on an exchange or to another person at price $ 44.46 per share. | 15 Mar 2023 | 13,656 | 374,702 (1%) | 0% | 44.5 | 607,146 | Common Stock |
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Sr. VP & CSO | Sale of securities on an exchange or to another person at price $ 43.92 per share. | 15 Mar 2023 | 269 | 388,358 (1%) | 0% | 43.9 | 11,814 | Common Stock |
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Sr. VP & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 13,017 | 382,454 (1%) | 0% | 0 | Common Stock | |
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Sr. VP & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 10,250 | 369,437 (1%) | 0% | 0 | Common Stock | |
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Sr. VP & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.77 per share. | 13 Feb 2023 | 7,752 | 374,702 (1%) | 0% | 52.8 | 409,073 | Common Stock |
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Sr. VP & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.33 per share. | 01 Dec 2022 | 1,055 | 359,187 (1%) | 0% | 44.3 | 46,768 | Common Stock |
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Sr. VP & CSO | 23 Nov 2022 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | ||
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Sr. VP & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 21,000 | 360,242 (1%) | 0% | 0 | Common Stock | |
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Sr. VP & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 2,419 | 340,195 (1%) | 0% | 0 | Common Stock | |
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Sr. VP & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.49 per share. | 14 Feb 2022 | 953 | 339,242 (1%) | 0% | 62.5 | 59,553 | Common Stock |
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Sr. VP & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 615 | 337,776 (1%) | 0% | 0 | Common Stock | |
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Sr. VP & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 87.68 per share. | 01 Dec 2021 | 557 | 337,161 (1%) | 0% | 87.7 | 48,838 | - |
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Sr. VP & CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 87.68 per share. | 01 Dec 2021 | 557 | 337,161 (1%) | 0% | 87.7 | 48,838 | - |
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Sr. VP & CSO | 19 Nov 2021 | 28,400 | 28,400 | - | - | Stock Option (right to buy) | ||
| Enanta Pharma Inc | Dr. Yat Sun Or, PhD | Sr. VP & CSO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 6,800 | 337,718 (1%) | 0% | 0 | Common Stock |